Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence.
about
Rapalogs in cancer prevention: anti-aging or anticancer?High glucose-mediated oxidative stress impairs cell migration.REDD1 protects osteoblast cells from gamma radiation-induced premature senescenceSuppression of replicative senescence by rapamycin in rodent embryonic cellsRapamycin induces pluripotent genes associated with avoidance of replicative senescencePseudo-DNA damage response in senescent cellsWhy men age faster but reproduce longer than women: mTOR and evolutionary perspectivesTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.Senescent vs. non-senescent cells in the human annulus in vivo: cell harvest with laser capture microdissection and gene expression studies with microarray analysis.Dynamic regulation of genetic pathways and targets during aging in Caenorhabditis elegans.Inhibition of S6K by resveratrol: in search of the purposeFrom rapalogs to anti-aging formula.Impact papers on aging in 2009.Paradoxical suppression of cellular senescence by p53Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts.Mechanisms underlying the anti-aging and anti-tumor effects of lithocholic bile acidBerberine suppresses gero-conversion from cell cycle arrest to senescence.Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.Cell size and growth rate are major determinants of replicative lifespan.Age-associated changes in basal NF-κB function in human CD4+ T lymphocytes via dysregulation of PI3 kinase.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marksInvolvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyCooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Molecular damage in cancer: an argument for mTOR-driven agingNCI's provocative questions on cancer: some answers to ignite discussion.Avian Reovirus Protein p17 Functions as a Nucleoporin Tpr Suppressor Leading to Activation of p53, p21 and PTEN and Inactivation of PI3K/AKT/mTOR and ERK Signaling Pathways.Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.Geroconversion: irreversible step to cellular senescenceHypoxia and gerosuppression: the mTOR saga continuesErlotinib antagonizes ABC transporters in acute myeloid leukemia.Answering the ultimate question "what is the proximal cause of aging?"Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
P2860
Q26866151-59051233-2E5B-4908-A3E7-542BB4A1ADDCQ27329542-B5C271CE-A108-459A-B3A5-916AD1833FB0Q28384621-8B95DD2E-38BD-43B2-8C22-56CB2853F7DBQ28571864-1500D134-C000-4334-B391-64CD271AB6F8Q28572137-C31969C2-17F4-44B8-98C9-60661E0BA0B2Q28583844-F47B8145-5DE5-4A66-87E7-FACA17BEC3EBQ28750492-A3C2FBFC-BFA4-4DFB-944C-F31D2EC8CBB9Q30419997-BC21FC3F-DA43-4F7F-90BD-E9B4FC7A14CFQ30533934-1088FC2B-E6D2-4385-B3DE-4BDC7326B6A5Q33527140-4F48D5CD-12D6-4BBA-A867-478219D4B95BQ33577722-96FA77C5-3E55-41E7-AD23-A08A8EF92D03Q33588762-44E8ECB5-B3FC-44E9-849A-18FB734DCDBFQ33829205-29482A2A-49DA-41DC-9617-FF19D172E8B8Q33854215-B004AF4B-99EB-440D-9DBC-DF0509CDCE24Q34006762-7D26309B-7A46-436A-B351-6D546E53C575Q34092485-198C006B-EACB-4CA3-A357-44FC4012A508Q34229984-A7B578AF-DB76-49AF-A2C5-813632678D65Q34358930-44F59D45-CC3F-48C0-B7C6-DC1665A2D25BQ34366519-EA2A50BE-725F-439D-AC06-7AA2926C83B6Q34621046-07625265-628B-4C79-8755-3A6F8DD334A7Q34621058-D7FE3C32-0B39-488B-9715-5F1797935B02Q34774284-5860BCC2-472D-455B-BB29-E6F939037A82Q34966603-869CC352-BF87-4DC2-A592-A52ADB5DF5B2Q35556981-34B82B68-B957-4AA7-ACE7-A148F8A1941FQ35582364-F23F4C6B-7A06-4011-B2A0-5403EB7037C2Q35640228-28F983C4-F700-4B01-BDBD-5CB5044D6C32Q35640301-EEC269B9-3185-4424-9A36-7FF6C3FD74AFQ35679353-5D5DF81C-43DC-4FBF-A1CB-23532E24B058Q35740772-D293591D-F116-4B2E-BBDF-E6358361333CQ35764401-2217829F-979C-4A04-92C3-E07576C5FBC4Q35921644-0B46DF5D-D7FC-465B-846F-C1DF6CB8BFC5Q35947377-F3C92DCF-5378-4C81-BC4B-2BEB9BA235EDQ36186369-AEB3A489-7D95-41E0-A05B-EE16DBD9AA8EQ36426478-64DD1DDD-4845-4373-BFFD-79FD517417DEQ36426524-F6FAA5E0-BEB7-43C7-8250-3B6618A4E4A4Q36736351-D7266E09-0489-4572-BD6F-369B13A509C6Q36736362-AE78D63F-436B-403D-B240-D74ABBF8C7F9Q36926148-9B850960-5D62-42BB-A433-DF1A33C377ECQ37192602-D09E94BF-F41B-4721-B8D9-82604552A404Q37192611-2B20EA40-FF41-44C4-A447-73B44C4397D2
P2860
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@en
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@nl
type
label
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@en
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@nl
prefLabel
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@en
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@nl
P356
P1433
P1476
Pharmacologic inhibition of ME ...... ecelerate cellular senescence.
@en
P2093
Michael Shtutman
Zoya N Demidenko
P304
P356
10.4161/CC.8.12.8809
P577
2009-06-21T00:00:00Z